The Impact of Plant-based Blends on Skeletal Muscle Protein Synthesis Rates in Older Adults

NCT05917223 | Active Not Recruiting

• 1 other identifier: 16408
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Lifestyle interventions such as physical activity and dietary habits are the most effective non-pharmacological strategies to combat the loss of muscle mass and the development of mobility limitations with aging. Resistance training (i.e., strengthening exercise) provides a strong stimulus to build muscle mass, and protein provides the essential building blocks. Therefore, an individual's dietary practices can influence the effectiveness of an exercise program - when combined, they work together to increase the muscle-building response. However, not all proteins are equally effective at bringing about muscle growth. Therefore, the purpose of this study is to investigate the effect of a higher-quality plant-based protein blend with lifting weight on muscle building in older men and women.

Conditions

Nutrition, Healthy

Keywords

Plant-based protein, Protein quality

Outcome Measures

Primary Outcomes (1)

• Muscle protein synthesis rate

  The rate of amino acids incorporation into skeletal muscle protein

  Over 5 hours after intervention

Secondary Outcomes (4)

• Plasma amino acid concentration

  Over 5 hours after intervention

• Muscle anabolic protein signaling

  At pre and 5 hours after intervention

• Plasma glucose

  Over 5 hours after intervention

• Plasma insulin

  Over 5 hours after intervention

Study Arms (4)

Milk protein ingestion

EXPERIMENTAL

Consuming 20 g of Milk Protein dissolved in 350mL of water, one time at the experiment visit

Dietary Supplement: Milk protein ingestion

Corn protein ingestion

EXPERIMENTAL

Consuming 20 g of Corn protein isolation dissolved in 350mL of water, one time at the experimental visit

Dietary Supplement: Cron protein ingestion

Corn+Pea protein ingestion

EXPERIMENTAL

Consuming 20 g of Corn+Pea protein isolation dissolved in 350mL of water, one time at the experimental visit

Dietary Supplement: Corn+Pea protein ingestion

Non-protein, low energy

EXPERIMENTAL

Consuming 20 g of carbohydrate dissolved in 350mL of water, one time at the experimental visit

Dietary Supplement: Non-protein, low energy

Interventions

Milk protein ingestion DIETARY_SUPPLEMENT

It's just an acute intervention, so the participant assigned to the Milk protein ingestion group will consume 20 g of milk protein during infusion protocol.

Milk protein ingestion

Cron protein ingestion DIETARY_SUPPLEMENT

It's just an acute intervention, so the participant assigned to the Corn protein ingestion group will consume 20 g of corn protein isolation during infusion protocol.

Corn protein ingestion

Corn+Pea protein ingestion DIETARY_SUPPLEMENT

It's just an acute intervention, so the participant assigned to the Corn+Pea protein ingestion group will consume 20 g of Corn+Pea protein isolation during infusion protocol.

Corn+Pea protein ingestion

Non-protein, low energy DIETARY_SUPPLEMENT

It's just an acute intervention, so the participant assigned to the Non-protein, low energy group will consume 20 g of carbohydrate during infusion protocol.

Non-protein, low energy

Eligibility Criteria

• Age: 60 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Older (60-80 y) men and women
• Be in good general health
• Non-smoking
• Recreationally active but not meet Canada's Physical Activity Guidelines (150 min of moderate-intensity exercise/week)
• Have a body mass index (BMI) between 18.5-30 kg/m2 (inclusive)
• Willing and able to provide informed consent (speaks and understands English)

You may not qualify if:

• Use of tobacco or related products
• Use assistive walking devices (e.g., cane or walker)
• Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the investigator, would compromise his/her ability to comply with the study requirements
• History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years
• Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, metabolic/endocrine, neuromuscular or bone wasting disorders
• Any cachexia-related condition (e.g., relating to cancer, tuberculosis or human immunodeficiency virus infection and acquired immune deficiency syndrome) or any genetic muscle diseases or disorders
• History of statin myalgia
• Current illnesses which could interfere with the study (e.g., prolonged severe diarrhea, regurgitation, difficulty swallowing)
• Excessive alcohol consumption (\>21 units/week)
• History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy (up to 81mg of baby aspirin per day taken as a prophylactic is permitted).
• Routine/daily usage of non-steroidal anti-inflammatory drugs (NSAIDS, prescription use or daily use of over-the-counter medication), use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), any anabolic steroid, creatine, whey protein supplements, casein or branched-chain amino acids (BCAAs) within 45 days prior to screening.
• A history of falls determined by a score \>25 on the Falls Efficacy Scale-International (FES-I).

Sponsors & Collaborators

• McMaster University: lead

Study Sites (1)

Ivor Wynne Centre

Hamilton, Ontario, L8S 4L8, Canada

Location

Study Officials

• Stuart Phillips, Ph.D.

  McMaster University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: This study is double-blind, placebo-controlled, randomized parallel control trial
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Model Details: This study is double-blind, placebo-controlled, randomized parallel control trial

Study Record Dates

• First Submitted: June 11, 2023
• First Posted: June 23, 2023
• Study Start: July 1, 2023
• Primary Completion: June 30, 2024
• Study Completion: May 31, 2025
• Last Updated: October 3, 2024

Record last verified: 2024-10

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)